Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 12/20 | 0.50 |
| ▸ | SLC5A1 | P13866 | 5/20 | 0.50 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1539332 | 0.84 | SLC5A2 (0.50) | SLC5A2SLC5A1KDM1A | |
| SCHEMBL28680327 | 0.84 | SLC5A2 (0.50) | SLC5A2SLC5A1KDM1AFFAR1KCNQ3 | |
| SCHEMBL14608649 | 0.79 | SLC5A2 (0.53) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL16601002 | 0.78 | SLC5A2 (0.45) | SLC5A2SLC5A1KDM1AFFAR1KCNQ3 | |
| SCHEMBL12801465 | 0.78 | KDM1A (0.50) | KDM1AKCNQ3KCNQ2 | |
| SCHEMBL10041206 | 0.76 | CYP3A4 (0.44) | — | |
| SCHEMBL13979827 | 0.74 | SLC5A2 (0.47) | SLC5A2SLC5A1 | |
| SCHEMBL16600928 | 0.73 | SLC5A2 (0.41) | SLC5A2SLC5A1KDM1AKCNQ3KCNQ2 | |
| SCHEMBL12257514 | 0.73 | SLC5A2 (0.73) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14954899 | 0.72 | SLC5A2 (0.40) | SLC5A2SLC5A1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012019496-A1 | C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION RPOCESS AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2012-02-16 | — | — | WO | disclosed |